Despite decades of progress, malaria continues to claim many lives, particularly among children in sub-Saharan Africa.
A major obstacle is that existing treatments can be complicated, requiring patients to take multiple doses precisely on schedule.
Researchers at the University of Dundee have identified a drug-like molecule known as cabamiquine that could ease this burden.
In early-stage clinical trials conducted in Africa, the compound demonstrated a reassuring safety profile in adults and adolescents.
Crucially, when paired with an established antimalarial called pyronaridine, it proved effective at clearing the infection.
The combination raises the prospect of shorter, simpler treatment regimens that patients are more likely to complete.
Such simplicity matters enormously in regions where healthcare access can be limited.
Still, the scientists caution that larger trials are essential before the therapy can be recommended broadly.